Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human BAY 2287411 in mesothelin-expressing solid tumors
NL-OMON50671Phase 1Active, not recruiting
- Sponsor
- Bayer
- Start
- Jan 2019
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Alpha Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Thorium-227 anetumab corixetan in mesothelioma, ovarian cancer and pancreatic cancer (PC), sponsored by Bayer. Primary endpoint: Incidence of dose-limiting toxicities. Started Jan 2019; status: active, not recruiting.
02
Drugs
Thorium-227 anetumab corixetan
03
Conditions
mesotheliomaovarian cancerpancreatic cancer (PC)
Beyond the preview
Go deeper on NL-OMON50671.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50671.